Intramuscular Administration: Patients with normal renal function: The recommended dosage for adults, children and older infants with normal renal function is 15 mg (potency)/kg/day divided into 2 or 3 equal doses administered at equally divided intervals.
Treatment of patients in the heavier weight classes should not exceed 15 g (potency)/day. When amikacin is indicated in newborns, it is recommended that a loading dose of 10 mg (potency)/kg be administered initially to be followed with 7.5 mg (potency)/kg every 12 hours.
The usual duration of treatment is 7 to 10 days. The total daily dose by all routes of administration should not exceed 15 mg (potency)/kg/day. At the recommended dosage level, uncomplicated infections due to amikacin-sensitive organisms should respond in 24 to 48 hours. If definite clinical response does not occur within 3 to 5 days, therapy should be stopped and the antibiotic susceptibility pattern of the invading organism should be rechecked. When amikacin is indicated in uncomplicated urinary tract infections, a dose of 250 mg (potency) twice daily may be used.
Patients with impaired renal function: Whenever possible, serum amikacin concentrations should be monitored by appropriate assay procedures.
Doses may be adjusted in patients with impaired renal function either by administering normal doses at prolonged intervals or by administering reduced doses at a fixed interval.
Intravenous Administration: The dose of amikacin sulfate are identical to the dose recommended for intramuscular administration. The solution for intravenous use is prepared by adding the contents of a 500 mg (potency) vial to 200 ml of sterile diluent such as Normal Saline or 5% Dextrose in Water. The solution is administered by intravenous infusion to adults and pediatric patients over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion. Dosage adjustment should be made according to the age and symptoms of the patient.